Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
Status:
Recruiting
Trial end date:
2022-10-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work
in treating patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal
gammopathy, and skin changes (POEMS) syndrome. Ixazomib citrate may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as
lenalidomide, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading.
Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used
with other drugs in the treatment of some types of cancer. Giving ixazomib citrate,
lenalidomide, and dexamethasone may work better in treating patients with POEMS syndrome.